4 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Resistance Research
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are delighted to share some highly cited papers on cancer resistance research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you. The list of relevant papers can be seen below:
“Mechanisms of Resistance to KRASG12C Inhibitors”
by Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall and Colin Lindsay
Cancers 2021, 13(1), 151; https://doi.org/10.3390/cancers13010151
Available online: https://www.mdpi.com/2072-6694/13/1/151
“Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance”
by Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin and Panagiotis Papageorgis
Cancers 2021, 13(17), 4363; https://doi.org/10.3390/cancers13174363
Available online: https://www.mdpi.com/2072-6694/13/17/4363
“Mechanisms of Resistance to Conventional Therapies for Osteosarcoma”
by Louise Marchandet, Morgane Lallier, Céline Charrier, Marc Baud’huin, Benjamin Ory and François Lamoureux
Cancers 2021, 13(4), 683; https://doi.org/10.3390/cancers13040683
Available online: https://www.mdpi.com/2072-6694/13/4/683
“Immune Resistance in Lung Adenocarcinoma”
by Magda Spella and Georgios T. Stathopoulos
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384
“Recent Insights into Therapy Resistance in Osteosarcoma”
by Zachary D. Prudowsky and Jason T. Yustein
Cancers 2021, 13(1), 83; https://doi.org/10.3390/cancers13010083
Available online: https://www.mdpi.com/2072-6694/13/1/83
“EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance”
by Mary Luz Uribe, Ilaria Marrocco and Yosef Yarden
Cancers 2021, 13(11), 2748; https://doi.org/10.3390/cancers13112748
Available online: https://www.mdpi.com/2072-6694/13/11/2748
Special Issues:
“The Role of Epithelial-Mesenchymal Transition in Therapies Resistance and Cancer Metastasis” Edited by: Dr. Pierre Savagner |
“State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers” Edited by: Dr. Yan Li
|
“Drug Resistance in Gastrointestinal Cancer” Edited by: Dr. Rosalba D’Alessandro and Dr. Carmelo Ferrai |
“Triple Negative Breast Cancer Therapy Resistance and Metastasis” Edited by: Dr. Daniela Sousa |